The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls

Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring

Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134 · see citing works

Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia

Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075 · see citing works

The Computational Anatomy of Psychosis

Adams, R. A., Stephan, K. E., Brown, H. R., Frith, C. D., & Friston, K. J. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00047 · Cited by 850 · see citing works

De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia

Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., Toncheva, D., Georgieva, L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.154 · Cited by 844 · see citing works

Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions

Javitt, D. C. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 563 · see citing works

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530 · see citing works

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · see citing works

Glutamate as a therapeutic target in psychiatric disorders

Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524 · see citing works

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

Preskorn, S., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 522 · see citing works

The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress

Olguı́n, H. J., Guzmán, D. C., García, E. H., & Mejía, G. B. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9730467 · Cited by 463 · see citing works

The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease

Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 438 · see citing works

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1313-x · Cited by 387 · see citing works

Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions

Jope, R. S., & Roh, M. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382 · see citing works

Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring

Zuckerman, L., & Weiner, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.08.008 · Cited by 352 · see citing works

What catatonia can tell us about “top-down modulation”: A neuropsychiatric hypothesis

Northoff, G. (2002) · Behavioral and Brain Sciences · doi:10.1017/s0140525x02000109 · Cited by 349 · see citing works

Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia

Becker, A., Peters, B., Schröeder, H., Mann, T., Huether, G., & Grecksch, G. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00080-0 · Cited by 339 · see citing works

NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders

Krystal, J. H., D’Souza, C., Petrakis, I. L., Belger, A., Berman, R., Charney, D. S., Abi‐Saab, W., & Madonick, S. H. (1999) · Harvard Review of Psychiatry · doi:10.3109/hrp.7.3.125 · Cited by 232 · see citing works

Role of endogenous sleep-wake and analgesic systems in anesthesia

Lu, J., Nelson, L. E., Franks, N., Maze, M., Chamberlin, N. L., & Saper, C. B. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21685 · Cited by 230 · see citing works

Glutamatergic model psychoses: prediction error, learning, and inference

Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.163 · Cited by 229 · see citing works

Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia

Javitt, D. C., Shelley, A.-M., Silipo, G., & Lieberman, J. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1131 · Cited by 4 · see citing works

Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia

Castner, S., Goldman-Rakic, P., & Williams, G. V. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1710-9 · Cited by 217 · see citing works

Ketamine

Wolff, K., & WINSTOCK, A. R. (2006) · CNS Drugs · doi:10.2165/00023210-200620030-00003 · Cited by 209 · see citing works

Adjunctive high-dose glycine in the treatment of schizophrenia

Javitt, D. C., Silipo, G. S., Cienfuegos, A., Shelley, A. M., Bark, N. M., Park, M., Lindenmayer, J., Suckow, R. F., & Zukin, S. R. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002590 · Cited by 199 · see citing works

Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia

Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194 · see citing works

Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer’s Disease

Minkeviciene, R., Banerjee, P., & Tanila, H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071027 · Cited by 184 · see citing works

Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat

López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183 · see citing works

Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors

Wiedholz, L. M., Owens, W. A., Horton, R. E., Feyder, M. J., Karlsson, R.-M., Hefner, K. R., Sprengel, R., Celikel, T., Daws, L. C., & Holmes, A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002056 · Cited by 180 · see citing works

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis

Heekeren, K., Daumann, J., Neukirch, A., Stock, C., Kawohl, W., Norra, C., Waberski, T. D., & Gouzoulis‐Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1129-4 · Cited by 152 · see citing works

Magnocellular contributions to impaired motion processing in schizophrenia

Kim, D., Wylie, G., Pasternak, R., Butler, P. D., & Javitt, D. C. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.10.008 · Cited by 146 · see citing works

Substance-Induced Psychoses: An Updated Literature Review

Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694863 · Cited by 146 · see citing works

Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Cyr, M., Calon, F., Morissette, M., & Paolo, T. D. (2002) · Journal of Psychiatry & Neuroscience · doi:10.1139/jpn.0202 · Cited by 162 · see citing works

Ketamine Dose-Dependently Induces High-Frequency Oscillations in the Nucleus Accumbens in Freely Moving Rats

Hunt, M. J., Raynaud, B., & Garcia, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.020 · Cited by 141 · see citing works

Drug models of schizophrenia

Steeds, H., Carhart-Harris, R. L., & Stone, J. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314557797 · Cited by 134 · see citing works

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.

Siuciak, J., Chapin, D., McCarthy, S. A., Guanowsky, V., Brown, J. A., Chiang, P., Marala, R., Patterson, T., Seymour, P., Swick, A., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.024 · Cited by 132 · see citing works

The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia

Sánchez‐Blázquez, P., Rodríguez-Muñoz, M., & Garzón, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00169 · Cited by 130 · see citing works

Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis

Teo, J., Edwards, M. J., & Bhatia, K. P. (2012) · Movement Disorders · doi:10.1002/mds.25107 · Cited by 129 · see citing works

Psychiatric safety of ketamine in psychopharmacology research

Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117 · see citing works

A Thalamo-Hippocampal-Ventral Tegmental Area Loop May Produce the Positive Feedback that Underlies the Psychotic Break in Schizophrenia

Lisman, J. E., Pi, H. J., Zhang, Y., & Otmakhova, N. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.007 · Cited by 115 · see citing works

Effects of Altered Excitation-Inhibition Balance on Decision Making in a Cortical Circuit Model

Lam, N. H., Borduqui, T., Hallak, J. E. C., Roque, A. C., Anticevic, A., Krystal, J. H., Wang, X., & Murray, J. D. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.1371-20.2021 · Cited by 115 · see citing works

An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray

Qin, S., Zhao, X., Pan, Y., Liu, J., Feng, G., Fu, J., Bao, J., Zhang, Z., & He, L. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201418 · Cited by 105 · see citing works

Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia

Ohtsuki, T., Sakurai, K., Dou, H., Toru, M., Yamakawa‐Kobayashi, K., & Arinami, T. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000808 · Cited by 100 · see citing works

Cellular perspectives on the glutamate–monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders

Pralong, É. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00017-5 · Cited by 99 · see citing works

A microsatellite repeat in the promoter of the N-methyl-d-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia

Itokawa, M., Yamada, K., Yoshitsugu, K., Toyota, T., Suga, T., Ohba, H., Watanabe, A., Hattori, E., Shimizu, H., Kumakura, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00006 · Cited by 98 · see citing works

Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research

Dauvermann, M. R., Lee, G. L., & Dawson, N. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13919 · Cited by 95 · see citing works

Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population

Martí, S. B., Cichon, S., Propping, P., & Nöthen, M. M. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1624 · Cited by 90 · see citing works

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

Siuciak, J., Chapin, D., McCarthy, S. A., & Martin, A. N. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0727-x · Cited by 97 · see citing works

A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo

Hunt, M. J., & Kasicki, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113495117 · Cited by 81 · see citing works

Phencyclidine/Schizophrenia: One View Toward the Past, The Other to the Future

Domino, E. F., & Luby, E. D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs011 · Cited by 81 · see citing works

The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications

Carty, N., Xu, J., Kurup, P., Brouillette, J., Goody, S. M. G., Austin, D. R., Yuan, P., Chen, G., Correa, P. R., Haroutunian, V., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.63 · Cited by 80 · see citing works

Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity

Ranlund, S., Adams, R. A., Díez, Á., Constante, M., Dutt, A., Hall, M., Maestro Carbayo, A., McDonald, C., Petrella, S., Schulze, K., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23035 · Cited by 77 · see citing works

Attractor-like dynamics in belief updating in schizophrenia

Adams, R. A., Napier, G., Roiser, J. P., Mathys, C., & Gilleen, J. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.3163-17.2018 · Cited by 77 · see citing works

Neuronal avalanches and coherence potentials

Plenz, D. (2012) · The European Physical Journal Special Topics · doi:10.1140/epjst/e2012-01575-5 · Cited by 72 · see citing works

Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol

Gaisler‐Salomon, I., & Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1311-z · Cited by 72 · see citing works

Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists

Krystal, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00102-5 · Cited by 71 · see citing works

Altered intrinsic and extrinsic connectivity in schizophrenia

Zhou, Y., Zeidman, P., Wu, S., Razi, A., Cheng Ann, C. H. E. N., Yang, L., Zou, J., Wang, G., Wang, H., & Friston, K. J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.12.006 · Cited by 66 · see citing works

Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system

van Coevorden‐Hameete, M. H., de Graaff, E., Titulaer, M. J., Hoogenraad, C. C., & Smitt, P. A. E. S. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.016 · Cited by 69 · see citing works

Serotonergic hallucinogens as translational models relevant to schizophrenia

Halberstadt, A. L., & Geyer, M. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000722 · Cited by 69 · see citing works

Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR

Fricker, A.-C., Mok, M. H. S., de la Flor, R., Shah, A. J., Woolley, M. L., Dawson, L. A., & Kew, J. N. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.03.002 · Cited by 68 · see citing works

D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons

Wang, Y., & Goldman‐Rakic, P. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400954101 · Cited by 67 · see citing works

Neurophysiological and neurochemical animal models of schizophrenia: Focus on glutamate

Bickel, S., & Javitt, D. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.005 · Cited by 70 · see citing works

Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia

Xu, K., Krystal, J. H., Ning, Y., Chen, D. C., He, H., Wang, D., Ke, X., Zhang, X., Ding, Y., Liu, Y., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.012 · Cited by 66 · see citing works

Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia

Cheng, W.-J., Chen, C.-H., Chen, C.-K., Huang, M.-C., Pietrzak, R. H., Krystal, J. H., & Xu, K. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.049 · Cited by 65 · see citing works

The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats

van der Meulen, J. A. J., Bilbija, L., Joosten, R. N. J. M. A., de Bruin, J. P. C., & Feenstra, M. G. P. (2003) · Neuroreport · doi:10.1097/00001756-200312020-00018 · Cited by 65 · see citing works

Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans

Mathalon, D. H., Ahn, K.-H., Perry, E. B., Cho, H. S., Roach, B. J., Blais, R. K., Bhakta, S. G., Ranganathan, M., Ford, J. M., & D’Souza, D. C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00003 · Cited by 64 · see citing works

Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA‐, α1‐ and 5‐HT2A‐receptors

Sebban, C., Tesolin, B., Ciprian‐Ollivier, J., Perret, L., & Spedding, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704451 · Cited by 64 · see citing works

Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis

Daumann, J., Wagner, D. R., Heekeren, K., Neukirch, A., Thiel, C. M., & Gouzoulis‐Mayfrank, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103227 · Cited by 62 · see citing works

Comparison of the Effects of Ketamine and Memantine on Prolactin and Cortisol Release in Men A Randomized, Double-blind, Placebo-controlled Trial

Hergovich, N. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00194-9 · Cited by 62 · see citing works

Do NMDA-R antagonists re-create patterns of spontaneous gamma-band activity in schizophrenia? A systematic review and perspective

Bianciardi, B., & Uhlhaas, P. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.005 · Cited by 60 · see citing works

Psychotropic and neurotropic activity

Vogel, H. G., & Vogel, W. H. (1997) · Springer eBooks · doi:10.1007/978-3-662-03333-3_5 · Cited by 60 · see citing works

Delta oscillation and short-term plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia

Kiss, T., Hoffmann, W. E., & Hajós, M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000271 · Cited by 56 · see citing works

AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes

Zhang, C., & Marek, G. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.009 · Cited by 56 · see citing works

Bayesian inference, predictive coding and delusions

Adams, R. A., Brown, H. R., & Friston, K. J. (2014) · Avant · doi:10.26913/50302014.0112.0004 · Cited by 54 · see citing works

Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis

Daumann, J., Heekeren, K., Neukirch, A., Thiel, C. M., Möller‐Hartmann, W., & Gouzoulis‐Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1237-1 · Cited by 52 · see citing works

Metabotropic glutamate 2/3 receptors as drug targets

Marek, G. J. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.003 · Cited by 52 · see citing works

Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia

Abram, S. V., Roach, B. J., Fryer, S. L., Calhoun, V. D., Preda, A., van Erp, T. G. M., Bustillo, J., Lim, K. O., Loewy, R. L., Stuart, B. K., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01502-0 · Cited by 49 · see citing works

The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development

Egerton, A., & Stone, J. M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 49 · see citing works

Subjective and physiological responses among racemic‐methadone maintenance patients in relation to relative (S)‐ vs. (R)‐methadone exposure

Mitchell, T. B., Dyer, K. R., Newcombe, D. A. L., Salter, A. B., Somogyi, A. A., Bochner, F., & White, J. M. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02221.x · Cited by 49 · see citing works

Identifying novel interventional strategies for psychiatric disorders: integrating genomics, ‘enviromics’ and gene–environment interactions in valid preclinical models

McOmish, C. E., Burrows, E. L., & Hannan, A. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12783 · Cited by 47 · see citing works

Inhibition of Return in the Human 5HT2A Agonist and NMDA Antagonist Model of Psychosis

Gouzoulis‐Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Daumann, J., Obradovic, M., & Kovar, K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300882 · Cited by 48 · see citing works

Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors

Javitt, D., Hashim, A., & Sershen, H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300589 · Cited by 48 · see citing works

Behavioral arousal and increased dopamine efflux after blockade of NMDA-receptors in the prefrontal cortex are dependent on activation of glutamatergic neurotransmission

Feenstra, M. G. P., Botterblom, M. H. A., & Uum, J. F. M. V. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00029-1 · Cited by 48 · see citing works

Exposure to enriched environments during adolescence prevents abnormal behaviours associated with histone deacetylation in phencyclidine-treated mice

Koseki, T., Mouri, A., Mamiya, T., Aoyama, Y., Toriumi, K., Suzuki, S., Nakajima, A., Yamada, T., Nagai, T., & Nabeshima, T. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001672 · Cited by 44 · see citing works

Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies

Ganesh, S., Cortes-Briones, J., Ranganathan, M., Radhakrishnan, R., Skosnik, P. D., & D’Souza, D. C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa031 · Cited by 44 · see citing works

Antisense knockdown of drebrin A, a dendritic spine protein, causes stronger preference, impaired pre-pulse inhibition, and an increased sensitivity to psychostimulant

Kobayashi, R., Sekino, Y., Shirao, T., Tanaka, S., Ogura, T., Inada, K., & Saji, M. (2004) · Neuroscience Research · doi:10.1016/j.neures.2004.02.014 · Cited by 42 · see citing works

Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats

Camarasa, J., Marimón, J. M., Rodrigo, T., Escubedo, E., & Pubill, D. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.05.014 · Cited by 42 · see citing works

Neurodegeneration in schizophrenia

Archer, T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.152 · Cited by 41 · see citing works

Ketamine Induces Dopamine-Dependent Depression of Evoked Hippocampal Activity in the Nucleus Accumbens in Freely Moving Rats

Hunt, M. J., Kessal, K., & Garcia, R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3800-04.2005 · Cited by 40 · see citing works

Altered brain structural and functional connectivity in schizotypy

Wang, Y.-M., Cai, X., Zhang, R., Zhang, Y.-J., Zhou, H., Wang, Y., Wang, Y., Huang, J., Wang, Y., Cheung, E. F. C., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720002445 · Cited by 39 · see citing works

NMDA receptor antagonist-enhanced high frequency oscillations: Are they generated broadly or regionally specific?

Olszewski, M., Dolowa, W., Matulewicz, P., Kasicki, S., & Hunt, M. J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.012 · Cited by 38 · see citing works

Treatment of negative and cognitive symptoms

Javitt, D. C. (1999) · Current Psychiatry Reports · doi:10.1007/s11920-999-0007-z · Cited by 38 · see citing works

mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia

Brambilla, C. R., Veselinović, T., Rajkumar, R., Mauler, J., Orth, L., Ruch, A., Ramkiran, S., Heekeren, K., Kawohl, W., Wyss, C., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24976 · Cited by 37 · see citing works

Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test

Langen, B., Dost, R., Egerland, U., Stange, H., & Hoefgen, N. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2567-y · Cited by 36 · see citing works

An updated overview of animal models in neuropsychiatry

Razafsha, M., Behforuzi, H., Harati, H., Wafai, R. A., Khaku, A. S., Mondello, S., Gold, M. S., & Kobeissy, F. H. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.02.045 · Cited by 36 · see citing works

Computational Neuropsychiatry – Schizophrenia as a Cognitive Brain Network Disorder

Dauvermann, M. R., Whalley, H. C., Schmidt, A., Lee, G. L., Romaniuk, L., Roberts, N., Johnstone, E. C., Lawrie, S. M., & Moorhead, T. W. J. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00030 · Cited by 35 · see citing works

Effects of Different Subanesthetic Doses of (S)-Ketamine on Neuropsychology, Psychopathology, and State of Consciousness in Man

Passie, T., Karst, M., Wiese, B., Emrich, H. M., & Schneider, U. (2005) · Neuropsychobiology · doi:10.1159/000085724 · Cited by 35 · see citing works

Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine

Cho, H. S., D’Souza, D. C., Gueorguieva, R. V., Perry, E. B., Madonick, S. H., Karper, L. P., Abi‐Dargham, A., Belger, A., Abi‐Saab, W., Lipschitz, D. S., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2066-5 · Cited by 35 · see citing works

Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency

Nagels, A., Kirner-Veselinovic, A., Krach, S., & Kircher, T. T. J. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.021 · Cited by 35 · see citing works

Psychiatric research: psychoproteomics, degradomics and systems biology

Kobeissy, F. H., Sadasivan, S., Liu, J., Gold, M. S., & Wang, K. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.293 · Cited by 34 · see citing works

Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered

Gaisler‐Salomon, I., Diamant, L., Rubin, C., & Weiner, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0960-3 · Cited by 34 · see citing works

Does ketamine mimic aspects of schizophrenic speech?

Covington, M. A., Riedel, W. J., Brown‐Johnson, C. G., He, C., Morris, E., Weinstein, S., Semple, J. M., & Brown, J. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077729 · Cited by 33 · see citing works

Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?

Large, C. H. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077712 · Cited by 94 · see citing works

Reviewing the ketamine model for schizophrenia

Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303 · see citing works

NMDA Antagonist-Induced Neurotoxicity and Psychosis

Noguchi, K. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-165-7_8 · Cited by 1 · see citing works

What value do NMDA receptor antagonist models of schizophrenia have for novel drug discovery?

Adell, A. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2562017 · Cited by 2 · see citing works

A State Dependence of the Response to N-Methyl-D-Aspartate Receptor Antagonism

Greene, R. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.011